Needling out Alzheimer’s
How AD vaccine UB-311 could be safer than other anti-beta amyloid therapies
United Neuroscience Ltd.’s pipeline comprises immunotherapeutic vaccines that selectively stimulate B cell responses against endogenous neurotoxic proteins. Its lead candidate UB-311 is an anti-beta amyloid vaccine for Alzheimer’s disease designed to improve cognition while avoiding the adverse events associated with prior AD vaccines and mAbs against the same target.
The first clinically tested AD vaccine, AN-1792 from Elan Corp. plc and Wyeth (now part of Pfizer Inc.), was able to activate natural antibody production